FLT3-ITD DNA allelic burden, but not mRNA levels, influences the biological characteristics of AML patients
By:
References
- 1. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia [Internet]. 2019;33(2):299–312. DOI: 10.1038/s41375-018-0357-910.1038/s41375-018-0357-9636538030651634
- 2. Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program [Internet]. 2013;2013:220–6. DOI: 10.1182/asheducation-2013.1.22010.1182/asheducation-2013.1.220471470924319184
- 3. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood [Internet]. 2017 Jan 26;129(4):424–47. DOI: 10.1182/blood-2016-08-73319610.1182/blood-2016-08-733196529196527895058
- 4. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776–84. DOI: 10.1182/blood-2007-08-10909010.1182/blood-2007-08-10909017957027
- 5. Pratcorona M, Brunet S, Nomdedeu J, Ribera JM, Tormo M, Duarte R, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood [Internet]. 2013 Apr 4;121(14):2734–8. DOI: 10.1182/blood-2012-06-43112210.1182/blood-2012-06-43112223377436
- 6. Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood [Internet]. 2014 Nov 27;124(23):3441–9. DOI: 10.1182/blood-2014-05-57807010.1182/blood-2014-05-57807025270908
- 7. Linch DC, Hills RK, Burnett AK, Khwaja A, Gale RE. Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood [Internet]. 2014 Jul 10;124(2):273–6. DOI: 10.1182/blood-2014-02-55466710.1182/blood-2014-02-55466724855211
- 8. Boddu PC, Kadia TM, Garcia‐Manero G, Cortes J, Alfayez M, Borthakur G, et al. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3 internal tandem duplication genotypes. Cancer [Internet]. 2019 Apr 6;125(7):1091–100. DOI: 10.1002/cncr.3188510.1002/cncr.31885656110130521114
- 9. Sakaguchi M, Yamaguchi H, Najima Y, Usuki K, Ueki T, Oh I, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv [Internet]. 2018 Oct 23;2(20):2744–54. DOI: 10.1182/bloodadvances.201802030510.1182/bloodadvances.2018020305619965630341082
- 10. Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, et al. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leuk Res [Internet]. 2018 Mar 1 [cited 2019 Jul 2];66:20–7.10.1016/j.leukres.2018.01.00829360622
- 11. Huang Y, Hu J, Lu T, Luo Y, Shi J, Wu W, et al. Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis. Cancer Manag Res [Internet]. 2019 May;Volume 11:4129–42. DOI: 10.2147/CMAR.S19452310.2147/CMAR.S194523651286031190985
- 12. Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, et al. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. Blood [Internet]. 2012 May 10;119(19):4383–6. DOI: 10.1182/blood-2010-12-32707210.1182/blood-2010-12-32707222374696
- 13. Cucchi DGJ, Denys B, Kaspers GJL, Janssen JJWM, Ossenkoppele GJ, de Haas V, et al. RNA-based FLT3 -ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML. Blood [Internet]. 2018 May 31;131(22):2485–9. DOI: 10.1182/blood-2017-12-81950810.1182/blood-2017-12-81950829669779
- 14. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93(9):3074–80.
- 15. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic patients from the United Kingdom Medical Research Council AML 10 and 12.pdf. Blood. 2001;98(6):1752–60. DOI: 10.1182/blood.V98.6.175210.1182/blood.V98.6.175211535508
- 16. Thiede C, Steudel C, Mohr B, Schaich M, Schaekel U, Bornhaeuser M, et al. Analysis of FLT3-activating mutations in 713 patients with acute myelogenous leukemia (AML): High prevalence in FAB-subtype M5 and identification of subgroups with poor prognosis. Blood. 2001;98(11, Part 1):2994.
- 17. Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, et al. Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia [Internet]. 2018 Feb 14;32(2):313–22. DOI: 10.1038/leu.2017.25710.1038/leu.2017.257580808028895560
Language: English
Page range: 33 - 41
Submitted on: Oct 1, 2020
Accepted on: Dec 11, 2020
Published on: Jan 29, 2021
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2021 Dan S. Soare, Eugen Radu, Ion Dumitru, Aurora Arghir, Cristina Enache, Horia Bumbea, Ana M. Vlădăreanu, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.